TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients Without Inhibitors
Brief Summary: This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older. The study evaluates two prophylactic emicizumab regimens versus no prophylaxis in this population with emphasis on efficacy, safety, and pharmacokinetics.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Intervention Type: BIOLOGICAL; Name: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Assigned to Arm(s): Cohort 1, Cohort 2 | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Cohort 1, Cohort 2
B: Arm Label: Arm C (Control): No Prophylaxis, Then Emicizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Emicizumab, Drug: Factor VIII (FVIII) | Arm Label: Arm A: Emicizumab 1.5 mg/kg QW; Type: EXPERIMENTAL; Interventions: Drug: Emicizumab, Drug: Factor VIII (FVIII) | Arm Label: Arm B: Emicizumab 3 mg/kg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Emicizumab, Drug: Factor VIII (FVIII) | Arm Label: Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis); Type: EXPERIMENTAL; Interventions: Drug: Emicizumab, Drug: Factor VIII (FVIII) | Intervention Type: DRUG; Name: Emicizumab; Assigned to Arm(s): Arm A: Emicizumab 1.5 mg/kg QW, Arm B: Emicizumab 3 mg/kg Q2W, Arm C (Control): No Prophylaxis, Then Emicizumab, Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis) | Intervention Type: DRUG; Name: Factor VIII (FVIII); Assigned to Arm(s): Arm A: Emicizumab 1.5 mg/kg QW, Arm B: Emicizumab 3 mg/kg Q2W, Arm C (Control): No Prophylaxis, Then Emicizumab, Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)
C: Arm Label: valoctocogene roxaparvovec; Type: EXPERIMENTAL; Interventions: Biological: valoctocogene roxaparvovec | Intervention Type: BIOLOGICAL; Name: valoctocogene roxaparvovec; Assigned to Arm(s): valoctocogene roxaparvovec
D: Arm Label: Group 1; Type: OTHER; Interventions: Genetic: Gene Transfer, Drug: scAAV2/8-LP1-hFIXco | Intervention Type: GENETIC; Name: Gene Transfer; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: scAAV2/8-LP1-hFIXco; Assigned to Arm(s): Group 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Influence of Postoperative Analgesia on Systemic Inflammatory Response and Postoperative Cognitive Disfunction in Elderly Patients After Surgical Repair of Femoral Fractures
Brief Summary: The purpose of this study is to determine whether epidural levobupivacaine applied for the purpose of post-operative analgesia compared to systemic analgesia with morphine leads to better pain control, stronger suppression of the inflammatory response and the production of inflammatory mediators, faster recovery of patients and consequently less incidence of postoperative cognitive dysfunction (POCD) in elderly patients after surgical treatment of femoral fractures.


Options:
A: Arm Label: Standard Care (SC); Type: SHAM_COMPARATOR; Interventions: Drug: Placebo: 3cc of 0.9% Normal Saline | Arm Label: Femoral Nerve Block (FNB); Type: EXPERIMENTAL; Interventions: Drug: Femoral nerve block: 25 mL of 0.5% bupivacaine | Intervention Type: DRUG; Name: Femoral nerve block: 25 mL of 0.5% bupivacaine; Assigned to Arm(s): Femoral Nerve Block (FNB) | Intervention Type: DRUG; Name: Placebo: 3cc of 0.9% Normal Saline; Assigned to Arm(s): Standard Care (SC)
B: Arm Label: Ropivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ropivacaine | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ropivacaine | Intervention Type: DRUG; Name: Ropivacaine; Assigned to Arm(s): Ropivacaine, Saline
C: Arm Label: morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: morphine | Arm Label: levobupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: levobupivacaine | Intervention Type: DRUG; Name: morphine; Assigned to Arm(s): morphine | Intervention Type: DRUG; Name: levobupivacaine; Assigned to Arm(s): levobupivacaine
D: Arm Label: Standard Treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Continuous fascia iliaca block; Type: EXPERIMENTAL; Interventions: Procedure: Continuous fascia iliaca block, Drug: Ropivacaine | Intervention Type: PROCEDURE; Name: Continuous fascia iliaca block; Assigned to Arm(s): Continuous fascia iliaca block | Intervention Type: DRUG; Name: Ropivacaine; Assigned to Arm(s): Continuous fascia iliaca block

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Clinical Trial on the Treatment of Caries Lesions Using Resin or Glass Ionomer Sealants in Permanent Teeth
Brief Summary: This study aimed to test whether sealing microcavitated ICDAS 3 carious lesions in permanent molars may be arrested by sealing using two different types of materials; a glass ionomer and a resin sealant. A Randomized controlled clinical trial was designed. Children between 6 and 12 years old were recruited and a total of 150 ICDAS 3 lesions in first permanent molars were allocated to one of the two arms of the study. Clinical and radiographic lesion progression were the main outcome. Integrity of the material and retention were secondary outcomes. A follow up period of 24 months with check-ups at 6 and 12 months was considered.


Options:
A: Arm Label: PP; Type: EXPERIMENTAL; Interventions: Procedure: PP | Arm Label: DPC; Type: OTHER; Interventions: Procedure: DPC | Intervention Type: PROCEDURE; Name: PP; Assigned to Arm(s): PP | Intervention Type: PROCEDURE; Name: DPC; Assigned to Arm(s): DPC
B: Arm Label: CHEMOMECHANICAL CARIES REMOVAL; Type: EXPERIMENTAL; Interventions: Procedure: Chemomechanical Caries Removal | Arm Label: conventional method; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional method | Intervention Type: PROCEDURE; Name: Chemomechanical Caries Removal; Assigned to Arm(s): CHEMOMECHANICAL CARIES REMOVAL | Intervention Type: PROCEDURE; Name: Conventional method; Assigned to Arm(s): conventional method
C: Arm Label: Glass Ionomer Sealant; Type: EXPERIMENTAL; Interventions: Drug: Sealants to arrest microcavitated caries. | Arm Label: Resin Sealant; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sealants to arrest microcavitated caries. | Intervention Type: DRUG; Name: Sealants to arrest microcavitated caries.; Assigned to Arm(s): Glass Ionomer Sealant, Resin Sealant
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Mechanical rotary burs | Arm Label: Conservative; Type: EXPERIMENTAL; Interventions: Device: Carisolv gel | Intervention Type: DEVICE; Name: Mechanical rotary burs; Assigned to Arm(s): Control | Intervention Type: DEVICE; Name: Carisolv gel; Assigned to Arm(s): Conservative

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Kg-Free: an Acceptance, Mindfulness and Compassionate-based Intervention for Women Struggling With Their Weight: A Randomized Controlled Trial
Brief Summary: This study aims to test the efficacy and feasibility of an acceptance, mindfulness and compassionate-based intervention for women with overweight and obesity without binge-eating disorder (Kg-Free). Kg-Free intervention comprises 10 weekly group sessions plus 2 booster fortnightly sessions (31/2months) 2h30 hours each, run in small groups at Coimbra's University Hospital. The main goal of Kg-Free intervention is to reduce weight self-stigma and unhealthy eating behaviours and promote quality-of-life by targeting weight-related experiential avoidance and self-criticism patterns. The intervention focuses on fostering a greater awareness and ability to be in contact, tolerate and accept all internal experiences (even the unwanted ones, such as craving for food, fatigue, stigma and shame), rather than trying to avoid, control or change them. Additionally, the intervention intents for participant's to develop a compassionate attitude towards themselves, especially during challenging times in order to decrease shame and self-criticism.


Options:
A: Arm Label: Diet Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Carbohydrate-restricted diet | Arm Label: Diet Education + Mindfulness; Type: EXPERIMENTAL; Interventions: Behavioral: Carbohydrate-restricted diet, Behavioral: Mindfulness | Intervention Type: BEHAVIORAL; Name: Carbohydrate-restricted diet; Assigned to Arm(s): Diet Education, Diet Education + Mindfulness | Intervention Type: BEHAVIORAL; Name: Mindfulness; Assigned to Arm(s): Diet Education + Mindfulness
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Behavioral: Meditation | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Behavioral: Meditation | Arm Label: Group 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Meditation; Assigned to Arm(s): Group 1, Group 2
C: Arm Label: Kg-Free; Type: EXPERIMENTAL; Interventions: Behavioral: Kg-Free, Other: Treatment as Usual | Arm Label: Treatment as Usual (TAU); Type: OTHER; Interventions: Other: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Kg-Free; Assigned to Arm(s): Kg-Free | Intervention Type: OTHER; Name: Treatment as Usual; Assigned to Arm(s): Kg-Free, Treatment as Usual (TAU)
D: Arm Label: Enhanced Usual Care (EUC); Type: OTHER; Interventions: Behavioral: Enhanced Usual Care, Diagnostic Test: Actigraph | Arm Label: Stress Management; Type: OTHER; Interventions: Behavioral: Stress Management, Diagnostic Test: Actigraph | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care (EUC) | Intervention Type: BEHAVIORAL; Name: Stress Management; Assigned to Arm(s): Stress Management | Intervention Type: DIAGNOSTIC_TEST; Name: Actigraph; Assigned to Arm(s): Enhanced Usual Care (EUC), Stress Management

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Brief Summary: To evaluate the efficacy and to compare efficacy and safety of BI 695501 versus Humira in patients with moderate to severe chronic plaque psoriasis.


Options:
A: Arm Label: Adalimumab; Type: OTHER; Interventions: Drug: adalimumab | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): Adalimumab
B: Arm Label: BI 695501; Type: EXPERIMENTAL; Interventions: Drug: BI 695501 | Arm Label: Humira; Type: ACTIVE_COMPARATOR; Interventions: Drug: Humira | Intervention Type: DRUG; Name: BI 695501; Assigned to Arm(s): BI 695501 | Intervention Type: DRUG; Name: Humira; Assigned to Arm(s): Humira
C: Arm Label: ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab 45 mg, ustekinumab 90 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Bimekizumab dosing regimen 1; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 2; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 3; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 4; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 5; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Bimekizumab dosing regimen 1, Bimekizumab dosing regimen 2, Bimekizumab dosing regimen 3, Bimekizumab dosing regimen 4, Bimekizumab dosing regimen 5 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Bimekizumab dosing regimen 1, Bimekizumab dosing regimen 2, Bimekizumab dosing regimen 3, Bimekizumab dosing regimen 4, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome
Brief Summary: This study investigates the use of methadone versus morphine wean for the treatment of neonatal abstinence syndrome for infants exposed to opioids in utero. Half of infants who require pharmacotherapy for NAS will receive a methadone wean, and half will receive a morphine wean. Length of hospital stay, length of treatment and parent satisfaction will be studied.


Options:
A: Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine
B: Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone
C: Arm Label: Neonatal Morphine Solution; Type: ACTIVE_COMPARATOR; Interventions: Drug: Neonatal Morphine Solution, Drug: Phenobarbital | Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone, Drug: Phenobarbital | Intervention Type: DRUG; Name: Neonatal Morphine Solution; Assigned to Arm(s): Neonatal Morphine Solution | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone | Intervention Type: DRUG; Name: Phenobarbital; Assigned to Arm(s): Methadone, Neonatal Morphine Solution
D: Arm Label: Low lactose formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Low lactose or regular formula | Arm Label: Regular formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Low lactose or regular formula | Intervention Type: OTHER; Name: Low lactose or regular formula; Assigned to Arm(s): Low lactose formula, Regular formula

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for participants with advanced/metastatic renal cell carcinoma (mRCC).

The primary hypotheses of this study are:

1. The combination therapy of pembrolizumab plus axitinib is superior to sunitinib monotherapy with respect to Progression-Free Survival (PFS) as assessed by blinded independent central imaging review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
2. The combination therapy of pembrolizumab plus axitinib is superior to sunitinib monotherapy with respect to Overall Survival (OS).


Options:
A: Arm Label: RAD001; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): RAD001 | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
B: Arm Label: pazopanib followed by sunitinib; Type: EXPERIMENTAL; Interventions: Drug: pazopanib, Drug: sunitinib | Arm Label: sunitinib followed by pazopanib; Type: EXPERIMENTAL; Interventions: Drug: pazopanib, Drug: sunitinib | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): pazopanib followed by sunitinib, sunitinib followed by pazopanib | Intervention Type: DRUG; Name: sunitinib; Assigned to Arm(s): pazopanib followed by sunitinib, sunitinib followed by pazopanib
C: Arm Label: Savolitinib; Type: EXPERIMENTAL; Interventions: Drug: Savolitinib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Savolitinib; Assigned to Arm(s): Savolitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
D: Arm Label: Pembrolizumab+Axitinib Combination Therapy; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Axitinib | Arm Label: Sunitinib Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab+Axitinib Combination Therapy | Intervention Type: DRUG; Name: Axitinib; Assigned to Arm(s): Pembrolizumab+Axitinib Combination Therapy | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib Monotherapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of a Booklet-Question List on Cancer Patients or Their Families Seeking Prognostic Information During a Palliative Care Consultation
Brief Summary: Prospective, randomized, multicentre phase III study to evaluate the level and type of information requested by patients or families during a palliative care consultation after they have been given the Booklet-Question List (BQL).


Options:
A: Arm Label: Feedback Group; Type: EXPERIMENTAL; Interventions: Behavioral: Communication Feedback Form for Patients with Serious Illness | Arm Label: Comparison/Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Communication Feedback Form for Patients with Serious Illness; Assigned to Arm(s): Feedback Group
B: Arm Label: video decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: video decision aid | Arm Label: Usual Care -- Verbal Description Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: video decision aid; Assigned to Arm(s): video decision aid
C: Arm Label: Clinicians with MI coaching; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational Interviewing | Arm Label: Wait-list control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Wait-list control | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): Clinicians with MI coaching | Intervention Type: BEHAVIORAL; Name: Wait-list control; Assigned to Arm(s): Wait-list control
D: Arm Label: Booklet-Question List (BQL) group; Type: N/A; Interventions: Other: Booklet-Question List | Arm Label: control group; Type: N/A; Interventions: N/A | Intervention Type: OTHER; Name: Booklet-Question List; Assigned to Arm(s): Booklet-Question List (BQL) group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy Study of Neural Progenitor Cell Transplantation and Paracrine Factors From Human Mesenchymal Stem Cells to Treat Newborn With Hypoxic-ischemic Encephalopathy
Brief Summary: The purpose of this study is to investigate the efficacy and safety of allogenic neural progenitor cell and paracrine factors of human mesenchymal stem cells for patients with moderate/severe Hypoxic-Ischemic Encephalopathy


Options:
A: Arm Label: Registry Cohort; Type: N/A; Interventions: Other: No Intervention | Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): Registry Cohort
B: Arm Label: PNEUMOSTEM®; Type: EXPERIMENTAL; Interventions: Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells | Intervention Type: BIOLOGICAL; Name: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells; Assigned to Arm(s): PNEUMOSTEM®
C: Arm Label: Neural progenitor cell; Type: EXPERIMENTAL; Interventions: Biological: neural progenitor cell | Arm Label: Paracrine factors; Type: EXPERIMENTAL; Interventions: Biological: Paracrine factors | Arm Label: Progenitor cell and paracrine factors; Type: EXPERIMENTAL; Interventions: Biological: progenitor cell and paracrine factors | Arm Label: Routine therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: neural progenitor cell; Assigned to Arm(s): Neural progenitor cell | Intervention Type: BIOLOGICAL; Name: Paracrine factors; Assigned to Arm(s): Paracrine factors | Intervention Type: BIOLOGICAL; Name: progenitor cell and paracrine factors; Assigned to Arm(s): Progenitor cell and paracrine factors
D: Arm Label: infusions; Type: EXPERIMENTAL; Interventions: Biological: infusion of autologous cord blood | Arm Label: historical control; Type: OTHER; Interventions: Other: Neurodevelopmental outcomes | Intervention Type: BIOLOGICAL; Name: infusion of autologous cord blood; Assigned to Arm(s): infusions | Intervention Type: OTHER; Name: Neurodevelopmental outcomes; Assigned to Arm(s): historical control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Using an Interactive System, a Paper and Pencil Program or Conventional Methodologies in the Rehabilitation of Stroke Patients: a Randomised Controlled Trial
Brief Summary: Virtual Reality allows the integration of both cognitive and motor rehabilitation in a more ecologically valid context. The purpose of this study is to determine whether this methodology has more impact on stroke rehabilitation than a paper and pencil personalised program and conventional therapy, which is motor-focused.


Options:
A: Arm Label: attention training acute; Type: EXPERIMENTAL; Interventions: Behavioral: APT training, Behavioral: Multiprofessional rehabilitation | Arm Label: attention training subacute; Type: EXPERIMENTAL; Interventions: Behavioral: APT training, Behavioral: Multiprofessional rehabilitation | Intervention Type: BEHAVIORAL; Name: APT training; Assigned to Arm(s): attention training acute, attention training subacute | Intervention Type: BEHAVIORAL; Name: Multiprofessional rehabilitation; Assigned to Arm(s): attention training acute, attention training subacute
B: Arm Label: Semi-immersive virtual training with shadow (S-IVTS); Type: EXPERIMENTAL; Interventions: Device: NIRVANA | Arm Label: Semi-immersive virtual training without shadow (S-IVT); Type: EXPERIMENTAL; Interventions: Device: NIRVANA | Intervention Type: DEVICE; Name: NIRVANA; Assigned to Arm(s): Semi-immersive virtual training with shadow (S-IVTS), Semi-immersive virtual training without shadow (S-IVT)
C: Arm Label: Virtual Reality; Type: EXPERIMENTAL; Interventions: Procedure: Virtual Reality | Arm Label: Paper and Pencil; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Paper and Pencil | Arm Label: Conventional Therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Therapy | Intervention Type: PROCEDURE; Name: Virtual Reality; Assigned to Arm(s): Virtual Reality | Intervention Type: PROCEDURE; Name: Paper and Pencil; Assigned to Arm(s): Paper and Pencil | Intervention Type: PROCEDURE; Name: Conventional Therapy; Assigned to Arm(s): Conventional Therapy
D: Arm Label: APT-II group; Type: EXPERIMENTAL; Interventions: Behavioral: Attention Process Training-II | Arm Label: standard care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Attention Process Training-II; Assigned to Arm(s): APT-II group

Answer: C